MedTrace Logo

A Study of the Safety, Tolerability and Pharmacokinetics of MEDI0618 in Healthy Volunteers

NCT04198558 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2023-10-16

No results posted yet for this study

Summary

This is a randomised, placebo-controlled study of the safety and tolerability of single doses of MEDI0618 in healthy volunteer subjects.

Conditions

Interventions

DRUG

MEDI0618

MEDI0618 A novel human immunoglobulin antibody

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Tharani Chessell, PhD · AstraZeneca

  • Stanislav Ignatenko, Medical Doctor · Charite Research Organisation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-29
Primary Completion
2022-02-23
Completion
2022-02-23

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04198558 on ClinicalTrials.gov